Compare · AMGN vs ATYR
AMGN vs ATYR
Side-by-side comparison of Amgen Inc. (AMGN) and aTyr Pharma Inc. (ATYR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and ATYR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $185.95B, about 2415.5x ATYR ($77.0M).
- Over the past year, AMGN is up 21.6% and ATYR is down 75.8% - AMGN leads by 97.4 points.
- AMGN has hit the wire 9 times in the past 4 weeks while ATYR has been quiet.
- AMGN has more recent analyst coverage (25 ratings vs 9 for ATYR).
- Company
- Amgen Inc.
- aTyr Pharma Inc.
- Price
- $344.50-1.18%
- $0.79+0.29%
- Market cap
- $185.95B
- $77.0M
- 1M return
- -2.63%
- +0.34%
- 1Y return
- +21.63%
- -75.81%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2015
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 9
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Latest AMGN
- AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS
- Amgen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
- SEC Form DEFA14A filed by Amgen Inc.
- Canaccord Genuity initiated coverage on Amgen with a new price target
- SEC Form DEFA14A filed by Amgen Inc.
- SEC Form DEFA14A filed by Amgen Inc.
- SEC Form DEF 14A filed by Amgen Inc.
- AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
- Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
Latest ATYR
- SEC Form DEFA14A filed by aTyr Pharma Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by aTyr Pharma Inc.
- SEC Form DEF 14A filed by aTyr Pharma Inc.
- SEC Form PRE 14A filed by aTyr Pharma Inc.
- SEC Form 10-K filed by aTyr Pharma Inc.
- aTyr Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
- aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
- President and CEO Shukla Sanjay converted options into 10,375 shares and sold $3,655 worth of shares (3,745 units at $0.98), increasing direct ownership by 5% to 153,553 units (SEC Form 4)